Mylan, Biocon launch biosimilar of cancer drug Herceptin in Australia

Biotechnology major Biocon and Mylan NV on Thursday launched biosimilar Ogivri, which is used for treatment of certain breast and stomach cancers in Australia.

It is a biosimilar of Hoffmann-La Roche's Herceptin.

Ogivri is the first trastuzumab biosimilar approved and launched in Australia and available on the Pharmaceutical Benefits Scheme (PBS), the companies said in a joint statement.

Biocon Biologics Chief Executive Officer Christiane Hamacher said, "We are excited to enable access to Ogivri, in Australia, a high-quality biosimilar trastuzumab, co-developed and manufactured by Biocon."